Italian-Turkish Economic Relations: an Overview
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Politecnico Di Torino
POLITECNICO DI TORINO Corso di Laurea Magistrale in Engineering Management Tesi di Laurea Magistrale Mergers & Acquisitions in Pharma Industry, Evidence from India and Italy Academic Supervisor Candidate Prof. Luigi Benfratello Vishal Singh S Co-supervisor: Mr Giacomo Bonaveglio A.A. 2018-19 Acknowledgement With due respect, I would like to take opportunity of expressing my sincere gratitude to Mr. Giacomo Bonaveglio and Professor Luigi Benfratello, my supervisors, for their continuous support, patient guidance and motivation. I would firmly like to thank Mr.Vinay Nagabhushana Rao and Mr.Shailesh Hegde, for their invaluable technical support to me from time to time. I also place on record my sincere thanks to my family and my friends here in Politecnico di Torino who has given me full co-operation through this master studies. i Abstract Mergers and Acquisitions are the most effective ways of accelerating the growth of companies. Pharmaceutical industries being one of the most dynamic sectors, probably see more merger and acquisition (M&A) activity than any other industry, both in the number of deals and the amount of money spent. No other industry can compare when it comes to M&As; large, game-changing deals continuously and profoundly change the competitive landscape, while smaller yet still significant transactions are an integral part the of operations of pharma companies. Pharma is a very large and complex growing part of the global economy. This thesis is structured around the world pharma market and the competitive environment we see, India’s Pharma market, its exports and Key players, the Italian pharma market and competition, Economic attractiveness of the pharma market in India. -
Breakthrough Ceremony for Monte Olibano Tunnel on the Cumana Railway Line
BREAKTHROUGH CEREMONY FOR MONTE OLIBANO TUNNEL ON THE CUMANA RAILWAY LINE The tunnel, built by Astaldi Group, allows for the upgrading and expansion of a strategic transport infrastructure for the metropolitan area of Naples and for the whole Phlegrean catchment area Naples, 2 July 2020 – The breakthrough ceremony for Monte Olibano tunnel, which forms part of the project to upgrade and expand the Cumana Railway, was held this morning in Naples and was attended by Vincenzo De Luca , President of Campania Region , Vincenzo Figliolia , Mayor of Pozzuoli , Umberto De Gregorio, Chairman of EAV , as well as Paolo Astaldi , Chairman of Astaldi Group , and Filippo Stinellis , CEO of Astaldi Group. The new tunnel forms part of the project to double the Cumana Railway line along a section measuring approximately 5 km and includes, inter alia, works to adjust the route of the old single-track Monte Olibano tunnel, construction of new stations in Pozzuoli and Cantieri, updating of Gerolomini station and works to double the railway track for the Dazio- Cantieri section. Performance of these works will make it possible to finally complete doubling of the railway line, allowing for an underground-style transport service on the complete Cumana line, with a high frequency of trains and high safety standards. Completion of the planned upgrading and expansion of the railway is scheduled for June 2023. The network, which comprises the Cumana and Circumflegrea lines and 33 stations, serves the whole of the western part of the Naples metropolitan area and the Phlegrean catchment area, a highly-populated area that is set to expand even further as a result of the constant growth of housing and tourism. -
Sold the Third Bosphorous Bridge in Turkey
ASTALDI: SOLD THE THIRD BOSPHOROUS BRIDGE IN TURKEY Rome, 19 March 2020 – Astaldi S.p.A. (“Astaldi” or the “Company”) informs that it has signed the closing on the sale of its interest in the concession for the construction and operation of the Northern Marmara Highway (the “Third Bridge”) in Turkey to IC Ictas Sanayi ve Ticaret A.S. (“Ictas”). The agreement signed with Ictas – already evaluated by the Court of Rome as offering the best protection of creditors within the composition procedure that Astaldi is currently carrying out – includes terms and conditions that are consistent with the composition proposal filed by the Company, and to wit: (i) the transfer to Ictas of the whole interest held by Astaldi in the Concessionaire of the Third Bridge (the “Concessionaire”) and of the relevant receivables, at a price of USD 315 million. This purchase price shall be paid net of a) the offsetting items with Ictas as per point (ii), b) the repayment of the other Turkish creditors (by virtue of the non-recognition of the composition arrangement in Turkey) for an amount of approximately EUR 142 million, in accordance with the arrangements provided for in the Composition Plan, as well as c) the relevant transaction cost; (ii) the waiving of any Ictas’ claim against Astaldi in relation to the projects in partnership, as a result of the getting out of said projects (both in Turkey and Russia); (iii) the purchase price, net of the items as per point (i) shall be paid in a single payment on receipt of the payment of the sale price by Ictas that the same is negotiating with a consortium of Chinese entrepreneurs (the “Chinese Consortium”) for selling the majority share of the capital of the same Concessionaire, or, in the absence of an agreement between Ictas and the Chinese Consortium, in annual instalments, in addition to the accrued interest, by the fourth quarter 2023. -
Interim Financial Report at 30 June 2017 Astaldi Group
Translation under review from the Italian original, that remains the definitive version Interim Financial Report at 30 June 2017 Astaldi Group 0 Translation under review from the Italian original, that remains the definitive version ASTALDI Società per Azioni Registered Office/Head Office: Via Giulio Vincenzo Bona 65 - 00156 Rome (Italy) Registered with the Companies Register of Rome Tax Code no.: 00398970582 R.E.A. no. 152353 VAT no. 0080281001 Share capital: EUR 196,849,800.00 fully paid-in 1 Interim Financial Report at 30 June 2017 | Astaldi Group Translation under review from the Italian original, that remains the definitive version Interim Report at 30 June 2017 _______________________________________________________________________________________ _ 4 _ GENERAL INFORMATION _ 7 _ INTERIM REPORT ON OPERATIONS _ 57 _ CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS MANAGEMENT CERTIFICATION MISSION Astaldi Group’s mission is to contribute to developing and improving the quality of life in the countries where it operates. It does so by adopting its own style, which sees design, construction and operation of major infrastructures go hand in hand with integration with the territory and training of the people involved. Astaldi translates ideas into reality, meeting the needs of its own customers and opening new paths to progress by constructing state-of-the-art works able to combine functionality and aesthetic beauty. Astaldi Group is representative of Italy as regards infrastructures worldwide. It has long exported technology, know-how and innovative solutions, establishing a real partnership with customers. Astaldi contributes to the affirmation of Italy’s excellence the world over, cultivating talent and optimising brilliance. 2 Interim Financial Report at 30 June 2017 | Astaldi Group Translation under review from the Italian original, that remains the definitive version ELT (Extremely Large Telescope), Chile (The world’s largest optical telescope) First Stone Ceremony for ELT | 26 May 2017. -
2019 Annual Report Annual 2019
a force for good. 2019 ANNUAL REPORT ANNUAL 2019 1, cours Ferdinand de Lesseps 92851 Rueil Malmaison Cedex – France Tel.: +33 1 47 16 35 00 Fax: +33 1 47 51 91 02 www.vinci.com VINCI.Group 2019 ANNUAL REPORT VINCI @VINCI CONTENTS 1 P r o l e 2 Album 10 Interview with the Chairman and CEO 12 Corporate governance 14 Direction and strategy 18 Stock market and shareholder base 22 Sustainable development 32 CONCESSIONS 34 VINCI Autoroutes 48 VINCI Airports 62 Other concessions 64 – VINCI Highways 68 – VINCI Railways 70 – VINCI Stadium 72 CONTRACTING 74 VINCI Energies 88 Eurovia 102 VINCI Construction 118 VINCI Immobilier 121 GENERAL & FINANCIAL ELEMENTS 122 Report of the Board of Directors 270 Report of the Lead Director and the Vice-Chairman of the Board of Directors 272 Consolidated nancial statements This universal registration document was filed on 2 March 2020 with the Autorité des Marchés Financiers (AMF, the French securities regulator), as competent authority 349 Parent company nancial statements under Regulation (EU) 2017/1129, without prior approval pursuant to Article 9 of the 367 Special report of the Statutory Auditors on said regulation. The universal registration document may be used for the purposes of an offer to the regulated agreements public of securities or the admission of securities to trading on a regulated market if accompanied by a prospectus or securities note as well as a summary of all 368 Persons responsible for the universal registration document amendments, if any, made to the universal registration document. The set of documents thus formed is approved by the AMF in accordance with Regulation (EU) 2017/1129. -
ASTALDI WILL BUILD the SUSPENSION BRIDGE OVER the DANUBE in the BRAILA AREA in ROMANIA Contract to Have a Total Value Equalling Approximately EUR 435 Million
ASTALDI WILL BUILD THE SUSPENSION BRIDGE OVER THE DANUBE IN THE BRAILA AREA IN ROMANIA Contract to have a total value equalling approximately EUR 435 million Rome, 17 January 2018 – Astaldi announces that, in a joint venture, it has been awarded the contract to build a suspension bridge over the Danube, in the Braila area in Romania. The value of the works totals approximately EUR 435 million, with Astaldi responsible for a 60% share. The contract calls for designing and building a suspension bridge totalling 1,975 metres in length, with a main span of 1,120 metres, and two side spans 490 and 365 metres long. Two bridge access viaducts, 110 metres in length, will also be built, in addition to 23 kilometres of connecting roads. For the performance of the works, one year is planned for design and 3 years for construction. The Customer is CNAIR, the state company headed by Romania’s Ministry of Transport and Infrastructure. The works are included in the Master Plan for the country’s transport, and are financed with dedicated EU funds under the Large Infrastructure Operational Programme (LIOP). The design and construction will be carried out in a joint venture by Astaldi (the leader, with a 60% share) with the Japanese company IHI (40%). IHI is the world leader in design and construction of suspension bridges and it has already worked with Astaldi for the construction of the Osman Gazi Bridge in Turkey, the world’s 4th longest suspension bridge and part of the Gebze-Orhangazi-Izmir Motorway. The Astaldi Group has been in Romania for more than 25 years, having already built more than 100 kilometres of railways and undergrounds, 250 kilometres of roads and motorways, and 2 international airports (Henri Coanda in Otopeni, Bucharest and Avram Iancu in Cluj-Napoca). -
Astaldi Group
Astaldi Group “The project resulted in an improved planning process and an improved CASE STUDY analysis of profit and loss and financial position. Furthermore, the project has been the catalyst for change management within the organization, including forecasting our profit and loss and financial positions based on individual customer projects. This has resulted in a 50% reduction in manual processes.” Company Marco Caucci Molara CEO, Astaldi Concessioni Astaldi Group Head of Strategic Planning and Control, Astaldi Industry The Challenge Construction Market growth and increased international investment created the need to collect and consolidate financial data from 16 countries on five continents, manage multiple Replacement currencies, analyze foreign exchange differences and associated impact and risks (i.e., hedging, multi-scenario and currency assumptions, cash pooling for operations) and Oracle-Hyperion Enterprise revamp the cash flow planning processes from a short-term to a medium-to-long-term forecasting horizon. Uses of CCH Tagetik Moreover, the need to support top management decision-making processes with an enterprise risk management application set the challenge to create a structured risk • Balance Sheet and Financial management methodology that could also be integrated with the business processes of Planning all groups. This also resulted in the need for stringent analysis, control, and constant • Managerial and Statutory monitoring of performance including foreign exchange differences, profit and loss Consolidation forecasting, and scenario analysis. • Budgeting • Executive Dashboard A few of Astaldi’s key requirements were the ability to plan cash flow at the project, company, sub-group and group levels, generate rolling cash flow forecasts, produce • Project Risk Management balance sheets by project, and create statements of uses, sources of funds, and invested • Disclosure Management capital. -
Salini Impregilo Starts Work on Sicily Rail Line
PRESS NOTE SICILY TO SEE JOB CREATION WITH CONSTRUCTION OF BICOCCA-CATENANUOVA RAILWAY SECTION MILAN, March 25, 2019 – “Today we celebrate in Sicily not only the start of a strategic project but also a relaunch of Sicily itself which, with this new section of the Palermo – Catania railway, welcomes this opportunity to further the development of the island’s infrastructure and create jobs in a region that has seen high levels of unemployment and a loss of workers to other areas of the country. This project alone will provide work for a combined total of 1,000 people , helping relaunch employment in the region for 1,000 families, especially Sicilian ones,” said Pietro Salini, Chief Executive of Salini Impregilo, at a ceremony celebrating the start of the €186-million project to expand the 38-kilometre Bicocca and Catenanuova section of the railway line between Palermo and Catania. The project belongs to a European Union initiative to create the so-called TEN-T network to connect and improve the functioning of the continent. “This is an important project for the people who will work on it as well as those who will eventually benefit from a faster connection between the two parts of the island. The effect that this project will have today and when it will be completed is proof of how much it is a priority for Italy to relaunch the entire infrastructure sector and create jobs. Our company has been present in Sicily for nearly 100 years but it has been away from it for 15 of them. -
105 (May, 2017)
ArAS News N E W S L E T T E R ARMENIAN ASTRONOMICAL SOCIETY (A r A S) No. 105 (May, 2017) ___________________________________________________________________ Editor: Sona FARMANYAN ArAS Newsletter online at: http://www.aras.am/ArasNews/arasnews.html ___________________________________________________________________ CONTENTS 1 IAU Symposia 2018 3 IVOA Interoperability 2 4-6 Report 3 MEARIM IV report 7 The Shaw Prize Foundation Announced 4 7 the Shaw Laureates for 2017 The Gruber Prize 5 Foundation Announced 8 the Laureate for 2017 First Stone Ceremony for 7 ESO's Extremely Large 9-10 Telescope The 2nd Astronomical Silk 6 11 Road ANSEF announces 2018 8 12 competition Release of Astrocurier 9 13 Newsletter May Issue Release of IAU Astronomy 10 Outreach Newsletter 2016 14 #1 Anniversaries: Benik TUMANIAN-100, 11 15-16 Nina IVANOVA-95, Nikolai Bochkarev-7019.05.1947 June Calendar of 12 17 Astronomical Events Meetings & Schools IAU Symposia 2018 The IAU Executive Committee has decided the list of the IAU symposia to be held in 2018; 3 before the IAU General Assembly (GA) and 7 during the IAU GA, totaling 10 IAU symposia in 2018. IAU S340: Long-term datasets for the understanding of solar and stellar magnetic cycles 19-23 Feb 2018, Jaipur, India IAU S341: Challenges in Panchromatic Modelling with Next Generation Facilities 02-06 Apr 2018, Osaka, Japan IAU S342: Perseus in Sicily: from black hole to cluster outskirts 14-18 May 2018, Noto, Italy IAU Symposia during the IAU General Assembly IAU S343: Why Galaxies Care About AGB Stars: A Continuing -
€200,000,000 5.875 Per Cent. Notes Due 15 December 2025 (To Be Consolidated and Form a Single Series with the €550,000,000 5.875 Per Cent
(incorporated with limited liability under the laws of the Republic of Italy) €200,000,000 5.875 per cent. Notes due 15 December 2025 (to be consolidated and form a single series with the €550,000,000 5.875 per cent. Notes due 15 December 2025 issued on 15 December 2020) Issue Price: 102 per cent. The issue price of the €200,000,000 5.875 per cent. Notes due 15 December 2025 (the “New Notes”) of Webuild S.p.A. (the “Issuer” or “Webuild”) is 102 per cent. of their principal amount (plus €1,416,438.36 accrued interest on the principal amount of the New Notes in respect of the period from, and including, 15 December 2020 to, but excluding, the New Issue Date (as defined below)). The New Notes will, on the Exchange Date (as defined in “Summary of Provisions Relating to the New Notes in Global Form” below), be consolidated and form a single series with the €550,000,000 5.875 per cent. Notes due 15 December 2025 (the “Original Notes” and, together with the New Notes, the “Notes”) of the Issuer issued on 15 December 2020 (the “Original Issue Date”). Unless previously redeemed or cancelled, the Notes will be redeemed at their principal amount on 15 December 2025. The Notes are subject to redemption, in whole but not in part, at their principal amount, plus interest, if any, to the date fixed for redemption at the option of the Issuer at any time in the event of certain changes affecting taxation in the Republic of Italy. -
Point-Of-Care Testing for Urinary Tract Infections Horizon Scan Report 0045 June 2016
Diagnostic Evidence Co-operative Oxford Point-of-care testing for urinary tract infections Horizon Scan Report 0045 June 2016 Clinical Question: In diagnosing patients with suspected urinary tract infections, what is the accuracy and utility of point-of- care tests compared to the current standard of urine microscopy, culture and antibiotic sensitivity analysis? Background, Current Practice and Advantages over Existing Technology: Background Urinary tract infections (UTIs) are among the most common types of infections, with an estimated 92 million people affected worldwide in 2013.1 The global burden of this disease is rising, with 16.1% increase in age- standardised incidence between 1990 and 2013 and 58,000 years lost to disability (YLD) in 2003 alone.1 UTIs are also a significant cause of mortality especially among the elderly population with 4835 deaths in England and Wales reported in 2012.2 UTI symptoms accounted for 1-3% of all primary care consultations3 and it was the main indication for 13.7% of community antibiotic prescriptions.4 The 1994/5 cost estimates of treating UTIs in the National Health Service were £124 million.5 Two decades on, it can only be assumed that with the rising prevalence of UTIs combined with the emergence of antibiotic-resistant organisms, the health and economic burden of the disease is likely to have increased. UTIs are broadly defined as infection of the urethra, bladder, ureters or kidneys by non-commensal micro- organisms, most commonly Escherichia coli, Staphylococcus saprophyticus and Enterococcus faecalis.6 Other causative uropathogens include Enterobacteriaceae sp. (Proteus mirabilis and Klebsiella sp.), group B streptococci, Pseudomonas aeruginosa, and Citrobacter sp. -
Bridging the Gap Between Research and Clinical Setting
About the MENARINI Group Menarini At-a-Glance The Menarini Group is a privately-held pharmaceutical and Headquarters: Florence, Italy biotechnology company with a proud 125 year history of delivering therapeutic, diagnostic, and medical device products to Founded: 1886 global healthcare markets. 2012 Turnover: €3.2 billion While Menarini has its roots in Italy, where it has ranked first for Global Workforce: 16,640 many years among those companies operating in the pharmaceutical sector, the Group has built a strong international Operating in more than 100 business and proudly claims 75% of it’s revenues coming from countries outside its home market. The research programs for the Group are divided up among its centres in Florence, Pomezia, Pisa, Barcelona and Berlin, addressing the medical needs in cardiovascular diseases, oncology and the asthma/pain/inflammation areas, primarily with a focus on the study of receptor antagonists. Menarini Biotech offers a secure, compliant and cost effective partner in the development and manufacture of biologic Milestones medicines derived from mammalian or microbial hosts. 1964 Laboratorios Menarini opens in A. Menarini Diagnostics has more than three decades dedicated to Barcelona (Spain) marking the exceeding the technological needs of Europe’s most prominent company’s first business outside Italy healthcare professionals in the fields of diabetes (both Home Glucose Testing and laboratory testing), autoimmunity, urinalysis and cell pathology. 1978 Menarini R&D division formed in conjunction with the introduction of pharmaceutical patents Group Turnover 1992 Berlin-Chemie acquired opening the Central-East European markets to Menarini 2003 Menarini Biotech created to provide product research, development and production capacities 2011 Menarini acquires the Invida Group consolidating and expanding presence in Asia-Pacific Via Dei Setti Santi 1/3 • Florence Italy 50131 • +39 (0)55 56801 www.menarini.com .